Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Angioedema in patients treated with sirolimus and ACE inhibitor post hematopoietic SCT

Bone Marrow Transplantation volume 49, pages 1448–1449 (2014)Cite this article

Subjects

Angiotensin-converting enzyme inhibitors (ACEi) are known to cause angioedema in 0.3–0.7% of patients.1,2 ACEi prevent degradation of bradykinin, resulting in vasodilation and increased vascular permeability. ACEi reduce proteinuria and have nephro-protective effects; therefore, this class of drugs is attractive in patients with sickle cell disease, where nephropathy is a common result of sickle-mediated tissue damage.3,4

Mammalian target of rapamycin (mTOR) is a serine/threonine kinase and regulates cellular metabolism, growth and proliferation. Sirolimus is an mTOR inhibitor and is widely used as an immunosuppressive agent to prevent rejection and/or GVHD in both solid organ and BM transplantation. Sirolimus has advantages over calcineurin inhibitors in induction of immune tolerance.5,6

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Kostis JB, Kim HJ, Rusnak J, Casale T, Kaplan A, Corren J et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med 2005; 165: 1637–1642.

    Article  CAS  Google Scholar 

  2. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. New Engl J Med 2008; 358: 1547–1559.

    Article  CAS  Google Scholar 

  3. Falk RJ, Scheinman J, Phillips G, Orringer E, Johnson A, Jennette JC . Prevalence and pathologic features of sickle cell nephropathy and response to inhibition of angiotensin-converting enzyme. New Engl J Med 1992; 14: 910–915.

    Article  Google Scholar 

  4. Guasch A, Cua M, Mitch WE . Early detection and the course of glomerular injury in patients with sickle cell anemia. Kidney Int 1996; 3: 786–791.

    Article  Google Scholar 

  5. Zheng Y, Collins SL, Lutz MA, Allen AN, Kole TP, Zarek PE et al. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J Immunol 2007; 4: 2163–2170.

    Article  Google Scholar 

  6. Waickman AT, Powell JD . Mammalian target of rapamycin integrates diverse inputs to guide the outcome of antigen recognition in T cells. J Immunol 2012; 10: 4721–4729.

    Article  Google Scholar 

  7. Stallone G, Infante B, Di Paolo S, Schena A, Grandaliano G, Gesualdo L et al. Sirolimus and angiotensin-converting enzyme inhibitors together induce tongue oedema in renal transplant recipients. Nephrol Dial Transplant 2004; 19: 2906–2908.

    Article  CAS  Google Scholar 

  8. Duerr M, Glander P, Diekmann F, Dragun D, Neumayer HH, Budde K . Increased incidence of angioedema with ACE inhibitors in combination with mTOR inhibitors in kidney transplant recipients. Clin J Am Soc Nephrol 2010; 4: 703–708.

    Article  Google Scholar 

  9. Brown NJ, Ray WA, Snowden M, Griffin MR . Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 1996; 60: 8–10.

    Article  CAS  Google Scholar 

  10. Pare G, Kubo M, Byrd JB, McCarty CA, Woodard-Crice A, Teo KK et al. Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema. Pharmacogenet Genomics 2013; 23: 470–478.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This research was supported by the intramural research program of the National Heart, Lung, and Blood Institute at the National Institutes of Health.

Author information

Authors and Affiliations

  1. Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA

    M Jung & C E Dunbar

  2. Department of Hematology and Oncology, Washington Hospital Center, Washington, DC, USA

    V N Ranpura

  3. Molecular and Clinical Hematology Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA

    J F Tisdale, C D Fitzhugh & M M Hsieh

Authors
  1. M Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V N Ranpura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C E Dunbar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J F Tisdale
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C D Fitzhugh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M M Hsieh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M M Hsieh.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jung, M., Ranpura, V., Dunbar, C. et al. Angioedema in patients treated with sirolimus and ACE inhibitor post hematopoietic SCT. Bone Marrow Transplant 49, 1448–1449 (2014). https://doi.org/10.1038/bmt.2014.162

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2014.162

This article is cited by

Search

Advanced search

Quick links